The vast majority of causes of thrombocytosis are acquired disorders, but in a few cases, they may be congenital, such as thrombocytosis due to congenital asplenia.
12.
Chemotherapy for polycythemia may be used, either for maintenance, or when the rate of bloodlettings required to maintain normal hematocrit is not acceptable, or when there is significant thrombocytosis or intractable pruritus.
13.
However, in primary thrombocytosis, if platelet counts are over 750, 000 or 1, 000, 000, and especially if there are other risk factors for thrombosis, treatment may be needed.
14.
Scientific literature sometimes excludes thrombocytosis from the scope of thrombophilia by definition, but practically, by the definition of thrombophilia as an increased predisposition to thrombosis, thrombocytosis ( especially primary thrombocytosis ) is a potential cause of thrombophilia.
15.
Scientific literature sometimes excludes thrombocytosis from the scope of thrombophilia by definition, but practically, by the definition of thrombophilia as an increased predisposition to thrombosis, thrombocytosis ( especially primary thrombocytosis ) is a potential cause of thrombophilia.
16.
Scientific literature sometimes excludes thrombocytosis from the scope of thrombophilia by definition, but practically, by the definition of thrombophilia as an increased predisposition to thrombosis, thrombocytosis ( especially primary thrombocytosis ) is a potential cause of thrombophilia.
17.
An abnormality or disease of the platelets is called a thrombocytopathy, which can be either a low number of platelets ( thrombocytopenia ), a decrease in function of platelets ( thrombasthenia ), or an increase in the number of platelets ( thrombocytosis ).
18.
Elevated platelet concentration is thrombocytosis and is either " congenital ", " reactive " ( to cytokines ), or due to " unregulated production " : one of the " myeloproliferative neoplasms " or certain other myeloid neoplasms.
19.
These include a multi-center Phase II trial involving 37 patients with V617F JAK2 positive polycythemia vera and essential thrombocytosis; results published in 2014 indicate that the trial did not achieve the endpoint of 15 % reduction of V617F JAK2 allele burden in 15 % of patients.
20.
"' Thrombocytosis "'( or "'thrombocythemia "') is the presence of high platelet counts in the blood, and can be either primary ( also termed essential and caused by a myeloproliferative disease ) or reactive ( also termed secondary ).
